Informa Pharma Intelligence：2021临床试验格局白皮书（英文版）（13页）.pdf

1、Clinical Trials Resilience After Pandemic DisruptionsHeidi Chen,PhDAssociate Director,Research&Commercial Support,Principal Analyst,CNS,Autoimmune/Inflammation&OphthalmologyThe Annual Clinical Trials Round-up 2021The Clinical Trial LandscapeWe saw an explosion of trials initiated in infectious disea

2、se,while clinical trials in other therapeutic areas endured setbacks in their enrollment and trial progression.With the uptake of vaccinations from late 2020 through 2021,and the rollercoasters of variants that dashed hopes of returns to normalcy,the entire healthcare industry is learning to coexist

3、 with COVID-19.As the industry continues to navigate new ground in this ever-changing climate,we will assess trends across Phase IIII clinical trials initiated in the year 2021,and see if the stories within the data can help us determine whether we have reached a“new normal”in this post-pandemic wor

4、ld.Certainly,recent experience has shown newfound resilience within the clinical trial ecosystem,through adaptive initiatives and trial design shifts that not only facilitated response to the pandemic,but also brought clinical trial innovations to the spotlight.2This years Clinical Trials Roundup is

5、 focused on an overview of the Phase IIII clinical trials that initiated in 2021 across all therapeutic areas(TAs)comprehensively covered by Trialtrove,as well as in-depth analyses into the key diseases,players,and geographies that impact the pharmaceutical industry post-pandemic.We will compare the

6、 trial activity landscapes with those of 2020 and 2019,to account for any insightful trends resulting from the pre-and post-COVID-19 era.As of 23 June 2022,Trialtrove captured 10,410 Phase IIII clinical trials investigating at least one drug and with a disclosed start date within the calendar year o